Cyclooxygenase 2 expression in barrett’s esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure

Digestive Diseases and Sciences

Volumn 46, Issue 4, 2001, Pages 785-789

  Shirvani, Vivian N ^a,b   Ouatu lascar, Rodica ^a,b   Kaur, Baljeet S ^a,b   Omary, M Bishr ^a,b   Triadafilopoulos, George ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett's esophagus; COX 2; Dysplasia

Indexed keywords

CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CONTROLLED STUDY; DYSPLASIA; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; BARRETT ESOPHAGUS; CYCLOOXYGENASE 2; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEROXIDASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0035036921     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010700400960     Document Type: Article

References (45)

1. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
2. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction
3. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus
4. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction
5. Barrett's esophagus. Prevalence and incidence of adenocarcinoma
6. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus
7. Barrett's esophagus. Comparison of benign and malignant cases
8. Barrett's esophagus: Development of dysplasia and adenocarcinoma
9. Barrett's esophagus correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma
10. Aspirin use and reduced risk of fatal colon cancer
11. Aspirin use and risk of fatal cancer
12. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
13. Aspirin and the risk of colorectal cancer in women
14. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
15. Reduced risk of large-bowel adenomas among aspirin users
16. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
17. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
18. Regression of rectal adenomas after colectomy and ileorectal anastomosis for familial adenomatous polyposis
19. Altered eicosanoid levels in human colon cancer
20. Towards a better aspirin
21. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
22. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester
23. Up-regulation of cyclo-oxygenase- 2 gene expression in human colorectal adenomas and adenocarcinomas
24. Expression of prostaglandin G/H Synthase-1 and - 2 protein in human colon cancer
25. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
26. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
27. Evaluation of cyclooxygenase- 2 inhibitor for potential chemopreventive properties in colon carcinogenesis
28. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
29. Aspirin and reduced risk of esophageal carcinoma
30. Aspirin use and lung, colon and breast cancer incidence in a prospective study
31. Antitumoral activity of indomethacin on experimental esophageal tumors
32. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
33. Cyclooxygenase- 2 expression in human esophageal carcinoma
34. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications
35. Elevated cyclooxy-genase- 2 levels in Min mouse adenomas
36. Aspirin use, cancer, and polyps of the large bowel
37. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
38. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study
39. Chemoprevention of spontaneous intestinal adenomas in the APC Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
40. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction
41. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
42. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
43. Δ716 knockout mice by inhibition of cyclooxygenase 2 (cox-2)
44. Inhibition of human colon cancer cel growth by selective inhibition of cyclooxygenase- 2
45. Cyclooxygenase-2 expression in Barrett's esophagus and esophageal adenocarcinoma: Ex vivo induction by bile salts and acid exposure